Viewing Study NCT02496767

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:35 AM
Ignite Modification Date: 2026-02-21 @ 11:34 PM
Study NCT ID: NCT02496767
Status: COMPLETED
Last Update Posted: 2020-09-09
First Post: 2015-07-10
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
Sponsor:
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Raw JSON

{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000690', 'term': 'Amyotrophic Lateral Sclerosis'}], 'ancestors': [{'id': 'D013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D016472', 'term': 'Motor Neuron Disease'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C572767', 'term': 'CK-2017357'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'medicalaffairs@cytokinetics.com', 'phone': '650-624-2929', 'title': 'MD Cytokinetics', 'organization': 'Cytokinetics, Inc.'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'AEs were collected from the first dose of open-label study drug through 28 days after the last dose of study drug.', 'description': 'An AE was treatment-emergent if it started or worsened in severity after the first dose of study drug (in either the open-label \\[OL\\] or double-blind \\[DB\\] phases). The onset date of a TEAE in the OL phase that continued uninterrupted for ≥96 hours in the DB placebo-controlled phase was the date of the first dose of DB study drug.\n\nFor patients randomized in the DB withdrawal phase, the onset date was on or before the last dose of study drug in the DB placebo-controlled phase.', 'eventGroups': [{'id': 'EG000', 'title': 'Open-label Lead-in: 250 mg Tirasemtiv', 'description': 'Open-label tirasemiv (125 mg twice daily) for 2 weeks', 'otherNumAtRisk': 744, 'deathsNumAtRisk': 744, 'otherNumAffected': 640, 'seriousNumAtRisk': 744, 'deathsNumAffected': 1, 'seriousNumAffected': 11}, {'id': 'EG001', 'title': 'Double-blind, Placebo-controlled: Group 1 - Placebo', 'description': 'Day 1 through Week 48: 2 placebo tablets twice daily', 'otherNumAtRisk': 188, 'deathsNumAtRisk': 188, 'otherNumAffected': 182, 'seriousNumAtRisk': 188, 'deathsNumAffected': 17, 'seriousNumAffected': 53}, {'id': 'EG002', 'title': 'Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv', 'description': 'Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM', 'otherNumAtRisk': 126, 'deathsNumAtRisk': 126, 'otherNumAffected': 125, 'seriousNumAtRisk': 126, 'deathsNumAffected': 8, 'seriousNumAffected': 30}, {'id': 'EG003', 'title': 'Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM', 'otherNumAtRisk': 126, 'deathsNumAtRisk': 126, 'otherNumAffected': 125, 'seriousNumAtRisk': 126, 'deathsNumAffected': 10, 'seriousNumAffected': 30}, {'id': 'EG004', 'title': 'Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM', 'otherNumAtRisk': 125, 'deathsNumAtRisk': 125, 'otherNumAffected': 125, 'seriousNumAtRisk': 125, 'deathsNumAffected': 8, 'seriousNumAffected': 32}, {'id': 'EG005', 'title': 'Double-blind, Withdrawal: Placebo', 'description': 'Following the 48-week double-blind, placebo-controlled phase of the study, patients in the placebo group continued placebo for an additional 4 weeks.', 'otherNumAtRisk': 132, 'deathsNumAtRisk': 132, 'otherNumAffected': 123, 'seriousNumAtRisk': 132, 'deathsNumAffected': 5, 'seriousNumAffected': 15}, {'id': 'EG006', 'title': 'Double-blind, Withdrawal: Tirasemtiv to Placebo', 'description': 'Following the 48-week double-blind, placebo-controlled phase of the study, approximately half the patients in a tirasemtiv group were re-randomized to placebo treatment for 4 weeks.', 'otherNumAtRisk': 103, 'deathsNumAtRisk': 103, 'otherNumAffected': 100, 'seriousNumAtRisk': 103, 'deathsNumAffected': 4, 'seriousNumAffected': 15}, {'id': 'EG007', 'title': 'Double-blind, Withdrawal: Tirasemtiv', 'description': 'Following the 48-week double-blind, placebo-controlled phase of the study, approximately half the patients in a tirasemtiv group were re-randomized to remain on tirasemtiv treatment (at the same dose received at the end of the double-blind, placebo-controlled phase) for 4 weeks.', 'otherNumAtRisk': 101, 'deathsNumAtRisk': 101, 'otherNumAffected': 95, 'seriousNumAtRisk': 101, 'deathsNumAffected': 5, 'seriousNumAffected': 11}], 'otherEvents': [{'term': 'Abdominal distension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 5}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 21}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 40}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 24}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 21}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 27}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 17}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 15}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 13}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 24}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 19}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 7}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 10}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 9}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 5}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Dry mouth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 14}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 8}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 8}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 7}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 7}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 8}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Dysphagia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 33}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 28}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 22}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 16}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 22}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 17}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 17}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Gastrooesophageal reflux disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 6}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 6}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 108}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 30}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 20}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 38}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 26}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 9}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 7}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 6}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Salivary hypersecretion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 19}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 14}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 9}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 14}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 11}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 42}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 22}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 12}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 22}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 22}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 12}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 10}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 9}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 204}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 61}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 43}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 54}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 50}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 32}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 32}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 23}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Gait disturbance', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 19}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 13}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 12}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 10}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 9}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 12}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 7}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 11}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Oedema peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 19}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 9}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 10}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 10}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 10}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 7}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Peripheral swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 9}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 6}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 13}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 30}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 19}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 20}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 12}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 7}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 5}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 17}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 9}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 12}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 12}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 9}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 18}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 34}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 15}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 23}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 18}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 5}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 6}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Laceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 13}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 8}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 13}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 12}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 5}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 2}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Ligament sprain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 12}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Post-traumatic pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 26}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 16}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 14}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 8}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 6}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 3}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Skin abrasion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 24}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 22}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 12}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 8}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 5}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Traumatic fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 12}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 3}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Weight decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 40}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 41}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 41}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 28}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 26}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 31}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 35}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Decreased appetite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 45}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 19}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 16}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 19}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 21}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 10}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 6}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 14}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 8}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 6}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 15}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 11}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 9}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 9}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 8}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 7}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 8}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Muscle spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 33}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 34}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 17}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 24}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 17}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 22}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 18}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 17}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Muscular weakness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 54}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 58}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 52}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 42}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 34}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 48}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 45}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 42}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Musculoskeletal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 22}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 9}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 8}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 6}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 10}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 10}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 6}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 12}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 5}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 6}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 5}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Neck pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 7}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 3}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 17}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 9}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 12}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 11}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 11}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 7}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 8}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Balance disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 19}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 6}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 6}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 4}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 361}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 45}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 47}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 55}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 56}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 11}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 21}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 15}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Dysarthria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 30}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 18}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 15}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 8}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 12}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 13}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 11}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 10}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 36}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 28}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 13}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 21}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 19}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 12}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 7}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Muscle contractions involuntary', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 15}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 8}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 12}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 5}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 7}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Muscle spasticity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 10}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 6}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 7}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 7}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 90}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 14}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 19}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 19}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 18}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 10}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Tremor', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 22}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 13}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 11}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 5}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 3}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Affect lability', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 6}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 8}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 5}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 15}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 19}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 14}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 13}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 24}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 13}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 15}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 10}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 21}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 22}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 8}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 24}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 23}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 14}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 9}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 14}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 31}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 25}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 23}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 25}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 30}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 19}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 19}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 18}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 26}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 12}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 16}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 7}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 12}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 7}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 26}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 35}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 17}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 22}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 18}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 22}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 13}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 13}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Nasal congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 11}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 12}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 11}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 7}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 8}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 5}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Respiratory failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 12}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 6}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 7}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 6}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 12}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 8}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 3}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Parathesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 8}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Musculoskeletal stiffness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 9}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 7}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Head injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 8}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Blood creatine phosphokinase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 7}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 2}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Pruritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 7}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Hyperhidrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 6}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Vertigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 19}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 13}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}], 'seriousEvents': [{'term': 'Arteriosclerosis coronary artery', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Atrial tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Cardiac arrest', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Cor pulmonale acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Stress cardiomyopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Supraventricular tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Ventricular fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Abdominal pain upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Dysphagia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 12}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Ileus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Intestinal polyp', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Oesophageal spasm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Pancreatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Death', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Device dislocation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Device malfunction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Euthanasia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Sudden death', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Cholecystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Cholelithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Drug hypersensitivity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Appendicitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Bacteraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Bronchitis bacterial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Bronchopneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Cellulitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Device related sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Klebsiella bacteraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Lobar pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Lower respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Otitis externa', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Otitis media acute', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Serratia bacteraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Tracheobronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Urosepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Accidental overdose', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Subdural haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Toxicity to various agents', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Traumatic arthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Traumatic fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Traumatic haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Traumatic intracranial haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Liver function test abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Oxygen saturation decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Pulmonary function test decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Weight decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Dehydration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Hypokalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Hyponatraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Malnutrition', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Intervertebral disc protrusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Genital neoplasm malignant female', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Lung cancer metastatic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Pancreatic carcinoma metastatic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Testicular cancer metastatic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Amyotrophic lateral sclerosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Basal ganglia stroke', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Cerebellar infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Cerebrovascular insufficiency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Clonus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Ischaemic stroke', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Loss of consciousness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Muscle spasticity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Thalamic infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Toxic encephalopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Transient ischaemic attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Tremor', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Abnormal behaviour', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Adjustment disorder with anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Completed suicide', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Hallucination, auditory', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Hallucination, visual', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Mania', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Mental status changes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Panic attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Cystitis interstitial', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Nephrolithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Urinary retention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Acute respiratory failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Bronchial secretion retention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Chronic obstructive pulmonary disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Hypercapnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Hypoventilation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Increased bronchial secretion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Pneumonia aspiration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Pulmonary embolism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Respiratory depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Respiratory distress', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Respiratory failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 6}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 6}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Sleep apnoea syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}, {'term': 'Deep vein thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 744, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 188, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 126, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 126, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 125, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 132, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 103, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 101, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (18.0)'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '188', 'groupId': 'OG000'}, {'value': '126', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}, {'value': '122', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Double-blind, Placebo-controlled: Group 1 - Placebo', 'description': 'Day 1 through Week 48: 2 placebo tablets twice daily'}, {'id': 'OG001', 'title': 'Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv', 'description': 'Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM'}, {'id': 'OG002', 'title': 'Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}, {'id': 'OG003', 'title': 'Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}], 'classes': [{'categories': [{'measurements': [{'value': '-14.354', 'spread': '1.2270', 'groupId': 'OG000'}, {'value': '-12.648', 'spread': '1.5165', 'groupId': 'OG001'}, {'value': '-13.742', 'spread': '1.6076', 'groupId': 'OG002'}, {'value': '-13.927', 'spread': '1.7213', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.3782', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Least squares mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.707', 'ciLowerLimit': '-2.089', 'ciUpperLimit': '5.503', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.9365', 'statisticalMethod': 'Repeated-measures mixed model', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.7625', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Least squares mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.612', 'ciLowerLimit': '-3.359', 'ciUpperLimit': '4.583', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.0245', 'statisticalMethod': 'Repeated-measures mixed model', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.8394', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Least squares mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.428', 'ciLowerLimit': '-3.711', 'ciUpperLimit': '4.566', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.1081', 'statisticalMethod': 'Repeated-measures mixed model', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '24 weeks', 'description': 'SVC was measured using a spirometer (in units of liters). Following 3 to 5 breaths at rest, the patients were instructed to take as deep an inspiration as possible followed by a maximum exhalation (blowing out all the air in their lungs). Values obtained were converted to % predicted values (ie, the test result as a percent of predicted values for patients of similar demographic and baseline characteristics \\[eg, height, age, sex\\], based on Knudson 83 normative values).', 'unitOfMeasure': '% predicted', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The data presented are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the ALSFRS-R Respiratory Domain Score at the End of 48 Weeks of Double-blind, Placebo-controlled Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '188', 'groupId': 'OG000'}, {'value': '126', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}, {'value': '122', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Double-blind, Placebo-controlled: Group 1 - Placebo', 'description': 'Day 1 through Week 48: 2 placebo tablets twice daily'}, {'id': 'OG001', 'title': 'Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv', 'description': 'Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM'}, {'id': 'OG002', 'title': 'Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}, {'id': 'OG003', 'title': 'Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}], 'classes': [{'categories': [{'measurements': [{'value': '-2.26', 'spread': '0.258', 'groupId': 'OG000'}, {'value': '-1.95', 'spread': '0.320', 'groupId': 'OG001'}, {'value': '-2.41', 'spread': '0.340', 'groupId': 'OG002'}, {'value': '-2.59', 'spread': '0.355', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.4521', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Least squares mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.31', 'ciLowerLimit': '-0.50', 'ciUpperLimit': '1.12', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.410', 'statisticalMethod': 'Repeated-measures mixed model', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.7120', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Least squares mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.16', 'ciLowerLimit': '-1.00', 'ciUpperLimit': '0.68', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.426', 'statisticalMethod': 'Repeated-measures mixed model', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.4510', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Least squares mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.33', 'ciLowerLimit': '-1.19', 'ciUpperLimit': '0.53', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.439', 'statisticalMethod': 'Repeated-measures mixed model', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '48 weeks', 'description': "The ALSFRS-R is used to measure the progression and severity of disease; it consists of 12 questions, assessing a patient's capability and independence in functional activities relevant to ALS, categorized in 4 domains: bulbar functions, fine motor tasks, gross motor tasks, and respiratory function. Respiratory function consists of 3 of the 12 questions, which assess dyspnea, orthopnea, and respiratory insufficiency. Each question is scored from 0 (indicating incapable or dependent) to 4 (normal). The sum of the response to these 3 questions represents the respiratory domain score. The respiratory domain score ranges from 0 to 12, with higher scores reflecting more normal function and lower scores reflecting more impaired function.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.'}, {'type': 'SECONDARY', 'title': 'Slope of Mega-score of Muscle Strength During the 48 Weeks of Double-blind, Placebo-controlled Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '188', 'groupId': 'OG000'}, {'value': '126', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}, {'value': '122', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Double-blind, Placebo-controlled: Group 1 - Placebo', 'description': 'Day 1 through Week 48: 2 placebo tablets twice daily'}, {'id': 'OG001', 'title': 'Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv', 'description': 'Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM'}, {'id': 'OG002', 'title': 'Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}, {'id': 'OG003', 'title': 'Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.1501', 'groupId': 'OG000', 'lowerLimit': '-0.1729', 'upperLimit': '-0.1272'}, {'value': '-0.1512', 'groupId': 'OG001', 'lowerLimit': '-0.1794', 'upperLimit': '-0.1230'}, {'value': '-0.1434', 'groupId': 'OG002', 'lowerLimit': '-0.1742', 'upperLimit': '-0.1126'}, {'value': '-0.1413', 'groupId': 'OG003', 'lowerLimit': '-0.1730', 'upperLimit': '-0.1095'}]}]}], 'analyses': [{'pValue': '0.9505', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.0011', 'ciLowerLimit': '-0.0374', 'ciUpperLimit': '0.0351', 'statisticalMethod': 'Repeated-measures mixed model', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.7336', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.0066', 'ciLowerLimit': '-0.0317', 'ciUpperLimit': '0.0450', 'statisticalMethod': 'Repeated-measures mixed model', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6593', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Mean Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.0088', 'ciLowerLimit': '-0.0303', 'ciUpperLimit': '0.0479', 'statisticalMethod': 'Repeated-measures mixed model', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '48 weeks', 'description': 'A hand-held dynomometer, with a scale of 0 to 300 pounds, was used to measure muscle strength and handgrip strength (bilateral); the muscle groups tested were: elbow flexion (bilateral), wrist extension (bilateral), knee extension (bilateral), and ankle dorsiflexion (bilateral). The muscle strength mega-score was calculated as the average of responses to all tested muscles as well as handgrip strength. The slope of muscle strength mega-score was the change over time (48 weeks) and analyzed using a mixed model that assumed a random slope effect. For this endpoint, negative values indicate a decline in muscle strength over time.', 'unitOfMeasure': 'pounds/day', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.'}, {'type': 'SECONDARY', 'title': 'Time to the First Occurrence of a Decline From Baseline in Percent Predicted SVC ≥ 20 Percentage Points or the Onset of Respiratory Insufficiency or Death All 48 Weeks of Double-blind, Placebo-controlled Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '188', 'groupId': 'OG000'}, {'value': '126', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}, {'value': '122', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Double-blind, Placebo-controlled: Group 1 - Placebo', 'description': 'Day 1 through Week 48: 2 placebo tablets twice daily'}, {'id': 'OG001', 'title': 'Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv', 'description': 'Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM'}, {'id': 'OG002', 'title': 'Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}, {'id': 'OG003', 'title': 'Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}], 'classes': [{'categories': [{'measurements': [{'value': '98', 'groupId': 'OG000'}, {'value': '58', 'groupId': 'OG001'}, {'value': '58', 'groupId': 'OG002'}, {'value': '57', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.2369', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Hazard Ratio (HR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.818', 'ciLowerLimit': '0.587', 'ciUpperLimit': '1.141', 'estimateComment': 'Hazard ratio for tirasemtiv vs placebo', 'statisticalMethod': 'Regression, Cox', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.9420', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Hazard Ratio (HR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.988', 'ciLowerLimit': '0.711', 'ciUpperLimit': '1.372', 'estimateComment': 'Hazard ratio for tirasemtiv vs placebo', 'statisticalMethod': 'Regression, Cox', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6853', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Hazard Ratio (HR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.933', 'ciLowerLimit': '0.668', 'ciUpperLimit': '1.304', 'estimateComment': 'Hazard ratio for tirasemtiv vs placebo', 'statisticalMethod': 'Regression, Cox', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '48 weeks', 'description': 'This endpoint evaluated the time to occurrence of a decline in percent predicted SVC (as measured by spirometry) of ≥ 20 percentage points, or the onset of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for ≥ 22 hours per day for ≥10 consecutive days), or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase.\n\nNote: The median time to a ≥ 20% decline in percent predicted SVC, onset of respiratory insufficiency, or death was 302 days for the placebo group and 359, 334, and 337 days for the 250 mg, 375 mg, and 500 mg tirasemtiv groups, respectively. The data presented for this endpoint are the number and percent of patients who met the endpoint.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.'}, {'type': 'SECONDARY', 'title': 'Time to the First Occurrence of a Decline in SVC to ≤ 50% Predicted, or the Onset of Respiratory Insufficiency, or Death During the 48 Weeks of Double-blind, Placebo-controlled Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '188', 'groupId': 'OG000'}, {'value': '126', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}, {'value': '122', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Double-blind, Placebo-controlled: Group 1 - Placebo', 'description': 'Day 1 through Week 48: 2 placebo tablets twice daily'}, {'id': 'OG001', 'title': 'Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv', 'description': 'Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM'}, {'id': 'OG002', 'title': 'Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}, {'id': 'OG003', 'title': 'Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}], 'classes': [{'categories': [{'measurements': [{'value': '57', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '32', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.7667', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Hazard Ratio (HR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.066', 'ciLowerLimit': '0.698', 'ciUpperLimit': '1.627', 'estimateComment': 'Hazard ratio for tirasemtiv vs placebo', 'statisticalMethod': 'Regression, Cox', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6619', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Hazard Ratio (HR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.904', 'ciLowerLimit': '0.577', 'ciUpperLimit': '1.419', 'estimateComment': 'Hazard ratio for tirasemtiv vs placebo', 'statisticalMethod': 'Regression, Cox', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.5856', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Hazard Ratio (HR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.882', 'ciLowerLimit': '0.561', 'ciUpperLimit': '1.386', 'estimateComment': 'Hazard ratio for tirasemtiv vs placebo', 'statisticalMethod': 'Regression, Cox', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '48 weeks', 'description': 'This endpoint evaluated the time to occurrence of a decline in SVC (as measured by spirometry) to ≤ 50% predicted, or the onset of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for ≥ 22 hours per day for ≥10 consecutive days), or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase.\n\nNote: The median time to a decline in SVC to ≤ 50% predicted, onset of respiratory insufficiency, or death was not estimable for the placebo group or the 375 mg tirasemtiv group. The median time was estimated as 363 and 351 days for the 250 mg and 500 mg tirasemtiv groups, respectively. The data presented for this endpoint are the number and percent of patients who met the endpoint.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the ALSFRS-R Total Score to the End of 48 Weeks of the Double-blind, Placebo-controlled Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '188', 'groupId': 'OG000'}, {'value': '126', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}, {'value': '122', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Double-blind, Placebo-controlled: Group 1 - Placebo', 'description': 'Day 1 through Week 48: 2 placebo tablets twice daily'}, {'id': 'OG001', 'title': 'Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv', 'description': 'Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM'}, {'id': 'OG002', 'title': 'Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}, {'id': 'OG003', 'title': 'Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}], 'classes': [{'categories': [{'measurements': [{'value': '-11.39', 'spread': '0.695', 'groupId': 'OG000'}, {'value': '-11.39', 'spread': '0.859', 'groupId': 'OG001'}, {'value': '-12.19', 'spread': '0.903', 'groupId': 'OG002'}, {'value': '-11.99', 'spread': '0.937', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.9991', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Least squares mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-2.17', 'ciUpperLimit': '2.17', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.103', 'statisticalMethod': 'Repeated-measures mixed model', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.4808', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Least squares mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.80', 'ciLowerLimit': '-3.04', 'ciUpperLimit': '1.43', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.138', 'statisticalMethod': 'Repeated-measures mixed model', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6082', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Least squares mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.60', 'ciLowerLimit': '-2.89', 'ciUpperLimit': '1.69', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.165', 'statisticalMethod': 'Repeated-measures mixed model', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': '48 weeks', 'description': "The ALSFRS-R is used to measure the progression and severity of disease; it consists of 12 questions, assessing a patient's capability and independence in functional activities relevant to ALS, categorized in 4 domains: gross motor tasks, fine motor tasks, bulbar functions, and respiratory function. Each question is scored from 0 (indicating incapable or dependent) to 4 (normal). The total score ranges from 0 to 48, with higher scores reflecting more normal function and lower scores reflecting more impaired function.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.'}, {'type': 'SECONDARY', 'title': 'Time to the First Use of Mechanical Ventilatory Assistance or Death During All 48 Weeks of Double-blind, Placebo-controlled Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '188', 'groupId': 'OG000'}, {'value': '126', 'groupId': 'OG001'}, {'value': '125', 'groupId': 'OG002'}, {'value': '122', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Double-blind, Placebo-controlled: Group 1 - Placebo', 'description': 'Day 1 through Week 48: 2 placebo tablets twice daily'}, {'id': 'OG001', 'title': 'Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv', 'description': 'Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM'}, {'id': 'OG002', 'title': 'Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}, {'id': 'OG003', 'title': 'Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}], 'classes': [{'categories': [{'measurements': [{'value': '60', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '33', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.2602', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Hazard Ratio (HR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.776', 'ciLowerLimit': '0.500', 'ciUpperLimit': '1.206', 'estimateComment': 'Hazard ratio for tirasemtiv vs placebo', 'statisticalMethod': 'Regression, Cox', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.6748', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Hazard Ratio (HR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.094', 'ciLowerLimit': '0.720', 'ciUpperLimit': '1.662', 'estimateComment': 'Hazard ratio for tirasemtiv vs placebo', 'statisticalMethod': 'Regression, Cox', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '0.7694', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Hazard Ratio (HR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.938', 'ciLowerLimit': '0.609', 'ciUpperLimit': '1.443', 'estimateComment': 'Hazard ratio for tirasemtiv vs placebo', 'statisticalMethod': 'Regression, Cox', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '48 weeks', 'description': 'This endpoint evaluated the time to occurrence of mechanical ventilatory assistance (defined as invasive or non-invasive ventilation for at least 2 hours over a 24-hour period for at least 5 consecutive days) or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase.\n\nNote: The median time to first use of mechanical ventilatory assistance or death was not estimable for all but the 375 mg tirasemtiv group (with a value of 367 days). As such the number and percent of patients who met the endpoint (ie, had mechanical ventilatory assistance or died) are presented.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The data provided are for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Open-label Lead-in: 250 mg Tirasemtiv', 'description': 'Open-label tirasemiv (125 mg twice daily) for 2 weeks'}, {'id': 'FG001', 'title': 'Double-blind, Placebo-controlled: Group 1 - Placebo', 'description': 'Day 1 through Week 48: 2 placebo tablets twice daily'}, {'id': 'FG002', 'title': 'Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv', 'description': 'Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM'}, {'id': 'FG003', 'title': 'Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet (125 mg) of tirasemtiv and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet (125 mg) of tirasemtiv and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}, {'id': 'FG004', 'title': 'Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}, {'id': 'FG005', 'title': 'Double-blind, Withdrawal: Placebo', 'description': 'Following the 48-week double-blind, placebo-controlled phase of the study, patients in the placebo group continued placebo for an additional 4 weeks.'}, {'id': 'FG006', 'title': 'Double-blind, Withdrawal: Tirasemtiv to Placebo', 'description': 'Following the 48-week double-blind, placebo-controlled phase of the study, approximately half the patients in a tirasemtiv group were re-randomized to placebo treatment for 4 weeks.'}, {'id': 'FG007', 'title': 'Double-blind, Withdrawal: Tirasemtiv', 'description': 'Following the 48-week double-blind, placebo-controlled phase of the study, approximately half the patients in a tirasemtiv group were re-randomized to remain on tirasemtiv treatment (at the same dose received at the end of the double-blind, placebo-controlled phase) for 4 weeks.'}], 'periods': [{'title': 'Open-label Lead-in Phase', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '744'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '565'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '179'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '176'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}]}, {'title': 'Double-blind, Placebo-controlled Phase', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '188'}, {'groupId': 'FG002', 'numSubjects': '126'}, {'groupId': 'FG003', 'numSubjects': '126'}, {'groupId': 'FG004', 'numSubjects': '125'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '132'}, {'groupId': 'FG002', 'numSubjects': '80'}, {'groupId': 'FG003', 'numSubjects': '65'}, {'groupId': 'FG004', 'numSubjects': '59'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '56'}, {'groupId': 'FG002', 'numSubjects': '46'}, {'groupId': 'FG003', 'numSubjects': '61'}, {'groupId': 'FG004', 'numSubjects': '66'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '13'}, {'groupId': 'FG002', 'numSubjects': '23'}, {'groupId': 'FG003', 'numSubjects': '43'}, {'groupId': 'FG004', 'numSubjects': '43'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'Progressive disease', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '13'}, {'groupId': 'FG002', 'numSubjects': '9'}, {'groupId': 'FG003', 'numSubjects': '8'}, {'groupId': 'FG004', 'numSubjects': '14'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '10'}, {'groupId': 'FG002', 'numSubjects': '6'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'Various', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '9'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '5'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}]}]}, {'title': 'Double-blind, Withdrawal Phase', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '132'}, {'groupId': 'FG006', 'numSubjects': '103'}, {'groupId': 'FG007', 'numSubjects': '101'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '126'}, {'groupId': 'FG006', 'numSubjects': '99'}, {'groupId': 'FG007', 'numSubjects': '96'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '6'}, {'groupId': 'FG006', 'numSubjects': '4'}, {'groupId': 'FG007', 'numSubjects': '5'}]}], 'dropWithdraws': [{'type': 'Progressive disease', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '4'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '1'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '2'}, {'groupId': 'FG007', 'numSubjects': '1'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '2'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '1'}]}]}], 'recruitmentDetails': 'Patients with familial or sporadic amyotrophic lateral sclerosis were enrolled at 79 sites in Belgium, Canada, France, Germany, Great Britain, Ireland, Italy, Netherlands, Portugal, Spain, and the United States. The first patient was screened on 03 September 2015 and the last subject completed on 27 September 2017.', 'preAssignmentDetails': 'All enrolled patients began open-label tirasemtiv (250 mg) in a 2-week lead-in phase. Completed patients were randomized (3:2:2:2) to placebo or tirasemtiv (250, 375, or 500 mg) for 48 weeks of double-blind treatment. After which, patients on tirasemtiv were re-randomized (1:1) to placebo or tirasemtiv (current dose) for a 4-week withdrawal phase.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '188', 'groupId': 'BG000'}, {'value': '126', 'groupId': 'BG001'}, {'value': '125', 'groupId': 'BG002'}, {'value': '122', 'groupId': 'BG003'}, {'value': '561', 'groupId': 'BG004'}]}], 'groups': [{'id': 'BG000', 'title': 'Double-blind, Placebo-controlled: Group 1 - Placebo', 'description': 'Day 1 through Week 48: 2 placebo tablets twice daily'}, {'id': 'BG001', 'title': 'Double-blind, Placebo-controlled: Group 2 - 250 mg Tirasemtiv', 'description': 'Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM'}, {'id': 'BG002', 'title': 'Double-blind, Placebo-controlled: Group 3 - 375 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet (125 mg) of tirasemtiv and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}, {'id': 'BG003', 'title': 'Double-blind, Placebo-controlled: Group 4 - 500 mg Tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM'}, {'id': 'BG004', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '55.9', 'spread': '10.63', 'groupId': 'BG000'}, {'value': '57.1', 'spread': '10.20', 'groupId': 'BG001'}, {'value': '57.4', 'spread': '9.09', 'groupId': 'BG002'}, {'value': '56.0', 'spread': '10.81', 'groupId': 'BG003'}, {'value': '56.5', 'spread': '10.24', 'groupId': 'BG004'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '65', 'groupId': 'BG000'}, {'value': '30', 'groupId': 'BG001'}, {'value': '42', 'groupId': 'BG002'}, {'value': '38', 'groupId': 'BG003'}, {'value': '175', 'groupId': 'BG004'}]}, {'title': 'Male', 'measurements': [{'value': '123', 'groupId': 'BG000'}, {'value': '96', 'groupId': 'BG001'}, {'value': '83', 'groupId': 'BG002'}, {'value': '84', 'groupId': 'BG003'}, {'value': '386', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}, {'title': 'Asian', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '10', 'groupId': 'BG004'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}]}, {'title': 'Black or African American', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '6', 'groupId': 'BG004'}]}, {'title': 'White', 'measurements': [{'value': '181', 'groupId': 'BG000'}, {'value': '123', 'groupId': 'BG001'}, {'value': '120', 'groupId': 'BG002'}, {'value': '117', 'groupId': 'BG003'}, {'value': '541', 'groupId': 'BG004'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Riluzole use at baseline', 'classes': [{'categories': [{'measurements': [{'value': '141', 'groupId': 'BG000'}, {'value': '95', 'groupId': 'BG001'}, {'value': '94', 'groupId': 'BG002'}, {'value': '92', 'groupId': 'BG003'}, {'value': '422', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Baseline Characteristics are provided for the Full Analysis Set, comprised of patients who received at least 1 dose of study drug during the randomized double-blind, placebo-controlled phase and had at least 1 post-randomization efficacy assessment (totaling 561 patients: 188, 126, 125, and 122 patients in Groups 1, 2, 3, and 4, respectively).'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2017-06-26', 'size': 1030021, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2020-05-06T12:09', 'hasProtocol': True}, {'date': '2017-06-26', 'size': 726069, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2020-05-06T12:11', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 744}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-09-03', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-08', 'dispFirstSubmitDate': '2018-03-29', 'completionDateStruct': {'date': '2017-09-27', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-08-21', 'studyFirstSubmitDate': '2015-07-10', 'dispFirstSubmitQcDate': '2018-03-29', 'resultsFirstSubmitDate': '2020-05-06', 'studyFirstSubmitQcDate': '2015-07-10', 'dispFirstPostDateStruct': {'date': '2018-04-02', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2020-09-09', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2020-06-17', 'studyFirstPostDateStruct': {'date': '2015-07-14', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2020-06-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-03-09', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change From Baseline to Week 24 of the Double-blind, Placebo-controlled Phase in Percent Predicted Slow Vital Capacity (SVC)', 'timeFrame': '24 weeks', 'description': 'SVC was measured using a spirometer (in units of liters). Following 3 to 5 breaths at rest, the patients were instructed to take as deep an inspiration as possible followed by a maximum exhalation (blowing out all the air in their lungs). Values obtained were converted to % predicted values (ie, the test result as a percent of predicted values for patients of similar demographic and baseline characteristics \\[eg, height, age, sex\\], based on Knudson 83 normative values).'}], 'secondaryOutcomes': [{'measure': 'Change From Baseline in the ALSFRS-R Respiratory Domain Score at the End of 48 Weeks of Double-blind, Placebo-controlled Treatment', 'timeFrame': '48 weeks', 'description': "The ALSFRS-R is used to measure the progression and severity of disease; it consists of 12 questions, assessing a patient's capability and independence in functional activities relevant to ALS, categorized in 4 domains: bulbar functions, fine motor tasks, gross motor tasks, and respiratory function. Respiratory function consists of 3 of the 12 questions, which assess dyspnea, orthopnea, and respiratory insufficiency. Each question is scored from 0 (indicating incapable or dependent) to 4 (normal). The sum of the response to these 3 questions represents the respiratory domain score. The respiratory domain score ranges from 0 to 12, with higher scores reflecting more normal function and lower scores reflecting more impaired function."}, {'measure': 'Slope of Mega-score of Muscle Strength During the 48 Weeks of Double-blind, Placebo-controlled Treatment', 'timeFrame': '48 weeks', 'description': 'A hand-held dynomometer, with a scale of 0 to 300 pounds, was used to measure muscle strength and handgrip strength (bilateral); the muscle groups tested were: elbow flexion (bilateral), wrist extension (bilateral), knee extension (bilateral), and ankle dorsiflexion (bilateral). The muscle strength mega-score was calculated as the average of responses to all tested muscles as well as handgrip strength. The slope of muscle strength mega-score was the change over time (48 weeks) and analyzed using a mixed model that assumed a random slope effect. For this endpoint, negative values indicate a decline in muscle strength over time.'}, {'measure': 'Time to the First Occurrence of a Decline From Baseline in Percent Predicted SVC ≥ 20 Percentage Points or the Onset of Respiratory Insufficiency or Death All 48 Weeks of Double-blind, Placebo-controlled Treatment', 'timeFrame': '48 weeks', 'description': 'This endpoint evaluated the time to occurrence of a decline in percent predicted SVC (as measured by spirometry) of ≥ 20 percentage points, or the onset of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for ≥ 22 hours per day for ≥10 consecutive days), or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase.\n\nNote: The median time to a ≥ 20% decline in percent predicted SVC, onset of respiratory insufficiency, or death was 302 days for the placebo group and 359, 334, and 337 days for the 250 mg, 375 mg, and 500 mg tirasemtiv groups, respectively. The data presented for this endpoint are the number and percent of patients who met the endpoint.'}, {'measure': 'Time to the First Occurrence of a Decline in SVC to ≤ 50% Predicted, or the Onset of Respiratory Insufficiency, or Death During the 48 Weeks of Double-blind, Placebo-controlled Treatment', 'timeFrame': '48 weeks', 'description': 'This endpoint evaluated the time to occurrence of a decline in SVC (as measured by spirometry) to ≤ 50% predicted, or the onset of respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for ≥ 22 hours per day for ≥10 consecutive days), or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase.\n\nNote: The median time to a decline in SVC to ≤ 50% predicted, onset of respiratory insufficiency, or death was not estimable for the placebo group or the 375 mg tirasemtiv group. The median time was estimated as 363 and 351 days for the 250 mg and 500 mg tirasemtiv groups, respectively. The data presented for this endpoint are the number and percent of patients who met the endpoint.'}, {'measure': 'Change From Baseline in the ALSFRS-R Total Score to the End of 48 Weeks of the Double-blind, Placebo-controlled Treatment', 'timeFrame': '48 weeks', 'description': "The ALSFRS-R is used to measure the progression and severity of disease; it consists of 12 questions, assessing a patient's capability and independence in functional activities relevant to ALS, categorized in 4 domains: gross motor tasks, fine motor tasks, bulbar functions, and respiratory function. Each question is scored from 0 (indicating incapable or dependent) to 4 (normal). The total score ranges from 0 to 48, with higher scores reflecting more normal function and lower scores reflecting more impaired function."}, {'measure': 'Time to the First Use of Mechanical Ventilatory Assistance or Death During All 48 Weeks of Double-blind, Placebo-controlled Treatment', 'timeFrame': '48 weeks', 'description': 'This endpoint evaluated the time to occurrence of mechanical ventilatory assistance (defined as invasive or non-invasive ventilation for at least 2 hours over a 24-hour period for at least 5 consecutive days) or death, whichever was first, during the 48-week double-blind, placebo-controlled treatment phase.\n\nNote: The median time to first use of mechanical ventilatory assistance or death was not estimable for all but the 375 mg tirasemtiv group (with a value of 367 days). As such the number and percent of patients who met the endpoint (ie, had mechanical ventilatory assistance or died) are presented.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['fast skeletal troponin activator', 'tirasemtiv', 'CK-2017357', 'double-blind', 'randomized', 'placebo-controlled'], 'conditions': ['Amyotrophic Lateral Sclerosis']}, 'referencesModule': {'references': [{'pmid': '39513379', 'type': 'DERIVED', 'citation': 'Simkins TJ, Kupfer S, Malik FI, Meng L, Rudnicki SA, Wei J, Shefner JM, Bowser R. Plasma neurofilament analysis in VITALITY-ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2025 Feb;26(1-2):103-112. doi: 10.1080/21678421.2024.2423707. Epub 2024 Nov 8.'}, {'pmid': '29402141', 'type': 'DERIVED', 'citation': 'Andrews JA, Cudkowicz ME, Hardiman O, Meng L, Bian A, Lee J, Wolff AA, Malik FI, Shefner JM. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):259-266. doi: 10.1080/21678421.2018.1426770. Epub 2018 Feb 6.'}]}, 'descriptionModule': {'briefSummary': 'This study assessed the effect of tirasemtiv versus placebo on respiratory function in patients with ALS.', 'detailedDescription': "CY 4031 was a multi-national, double-blind, randomized, placebo-controlled, stratified, parallel group study of tirasemtiv in patients with ALS. The study had three phases: an open-label phase (2 weeks), a double-blind, placebo-controlled phase (48 weeks), and a double-blind, placebo-controlled tirasemtiv withdrawal phase (4 weeks). Patients who completed 2 weeks of treatment with open-label tirasemtiv (125 mg twice daily) were randomized 3:2:2:2 to placebo or one of three dose levels of tirasemtiv (250 mg/day, 375 mg/day, or 500 mg/day). Approximately 600 patients were planned to be enrolled into the open-label treatment phase.\n\nPatients taking riluzole at study entry could continue use of riluzole during the study as long as they had been on a stable dose for at least 30 days prior to study screening. In addition, for patients randomized to tirasemtiv, the riluzole dose was reduced to half the approved dose (ie, reduced to 50 mg once daily) because administration of tirasemtiv approximately doubles the exposure to concomitant riluzole. Patients randomized to placebo continued riluzole at 50 mg twice daily. This was accomplished without unmasking the study's blind as follows:\n\n1. All patients on riluzole took their morning 50 mg dose of riluzole from their personal riluzole supply.\n2. The sponsor supplied the evening riluzole dose as double-blind study medication, as follows: (a) for patients randomized to placebo, the double-blind, evening riluzole dose was 50 mg of active riluzole; (b) for patients randomized to tirasemtiv, the double-blind, evening riluzole dose was a matching placebo for riluzole."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria) ≤ 24 months prior to screening\n* Upright SVC ≥ 70 % of predicted for age, height and sex\n* Able to swallow tablets without crushing, and in the opinion of the Investigator, is expected to continue to be able to do so during the trial\n* A caregiver if one is needed\n* Clinical laboratory findings within the normal range or, if outside the normal range, deemed not clinically significant by the Investigator\n* Male patients must agree for the duration of the study and 10 weeks after the end of the study to use a condom during sexual intercourse with female partners who are of childbearing potential (i.e., following menarche until post-menopausal if not anatomically and physiologically incapable of becoming pregnant) and to have female partners use an additional effective means of contraception (e.g., diaphragm plus spermicide, or oral contraceptives) or the male patient must agree to abstain from sexual intercourse during and for 10 weeks after the end of the study, unless the male patient has had a vasectomy and confirmed sperm count is zero\n* Female patients must be post-menopausal (≥ 1 year) or sterilized, or, if of childbearing potential, not be breastfeeding, have a negative pregnancy test, have no intention to become pregnant during the course of the study, and use effective contraceptive drugs or devices while requiring male partner to use a condom for the duration of the study and for 10 weeks after the end of the study\n* Patients must be either on a stable dose of riluzole 50 mg twice daily for at least 30 days prior to screening or have not taken riluzole for at least 30 days prior to screening and are willing not to begin riluzole use until they complete study drug dosing\n\nExclusion Criteria:\n\n* At the time of screening, any use of non-invasive positive pressure ventilation (NIPPV, e.g. continuous positive airway pressure \\[CPAP\\] or bi-level positive airway pressure \\[BiPAP\\]) for any portion of the day, or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation\n* Patients with a diaphragm pacing system (DPS) at study entry or who anticipate DPS placement during the course of the study\n* BMI of 20.0 kg/m2 or lower\n* Unwilling or unable to discontinue tizanidine and theophylline-containing medications during study participation\n* Serum chloride outside the normal reference range\n* Neurological impairment due to a condition other than ALS, including history of transient ischemic attack within the past year\n* Presence at screening of any medically significant cardiac, pulmonary, GI, musculoskeletal, or psychiatric illness that might interfere with the patient's ability to comply with study procedures or that might confound the interpretation of clinical safety or efficacy data, including, but not limited to:\n\n 1. Poorly controlled hypertension\n 2. NYHA Class II or greater congestive heart failure\n 3. Chronic obstructive pulmonary disease or asthma requiring daily use bronchodilator medications\n 4. GI disorder that might impair absorption of study drug\n 5. History of significant liver disease defined by bilirubin \\> 2 times the upper limit of normal (ULN) or ALT or AST \\> 3 times the ULN on repeat testing\n 6. Poorly controlled diabetes mellitus\n 7. History of vertigo within three months of study entry\n 8. History of syncope without an explainable or treated cause\n 9. History of untreated intracranial aneurysm or poorly controlled seizure disorder\n 10. Amputation of a limb\n 11. Cognitive impairment, related to ALS or otherwise, sufficient to impair the patient's ability to give informed consent and to understand and/or comply with study procedures\n 12. Cancer with metastatic potential (other than basal cell carcinoma, carcinoma in situ of the cervix, or squamous cell carcinoma of the skin excised with clean margins) diagnosed and treated within the last two years\n 13. Any other condition, impairment or social circumstance that, in the opinion of the Investigator, would render the patient not suitable to participate in the study\n 14. Patient judged to be actively suicidal or a suicide risk by the Investigator\n* Has taken any investigational study drug within 30 days or five half-lives of the prior agent, whichever is greater, prior to dosing\n* Prior participation in any form of stem cell therapy for the treatment of ALS\n* Previously received tirasemtiv in any previous clinical trial"}, 'identificationModule': {'nctId': 'NCT02496767', 'acronym': 'VITALITY-ALS', 'briefTitle': 'Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year', 'organization': {'class': 'INDUSTRY', 'fullName': 'Cytokinetics'}, 'officialTitle': 'A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)', 'orgStudyIdInfo': {'id': 'CY 4031'}, 'secondaryIdInfos': [{'id': '2014-005413-23', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'Group 1 - Placebo', 'description': 'Day 1 through Week 48: 2 placebo tablets twice daily', 'interventionNames': ['Drug: Placebo tablets']}, {'type': 'EXPERIMENTAL', 'label': 'Group 2 - 250 mg tirasemtiv', 'description': 'Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM', 'interventionNames': ['Drug: Tirasemtiv', 'Drug: Placebo tablets']}, {'type': 'EXPERIMENTAL', 'label': 'Group 3 - 375 mg tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM', 'interventionNames': ['Drug: Tirasemtiv', 'Drug: Placebo tablets']}, {'type': 'EXPERIMENTAL', 'label': 'Group 4 - 500 mg tirasemtiv', 'description': 'Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM', 'interventionNames': ['Drug: Tirasemtiv', 'Drug: Placebo tablets']}], 'interventions': [{'name': 'Tirasemtiv', 'type': 'DRUG', 'otherNames': ['CK-2017357'], 'armGroupLabels': ['Group 2 - 250 mg tirasemtiv', 'Group 3 - 375 mg tirasemtiv', 'Group 4 - 500 mg tirasemtiv']}, {'name': 'Placebo tablets', 'type': 'DRUG', 'armGroupLabels': ['Group 1 - Placebo', 'Group 2 - 250 mg tirasemtiv', 'Group 3 - 375 mg tirasemtiv', 'Group 4 - 500 mg tirasemtiv']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85013', 'city': 'Phoenix', 'state': 'Arizona', 'country': 'United States', 'facility': "St. Joseph's Hospital & Medical Center - Barrow Neurology Clinics", 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '92093', 'city': 'La Jolla', 'state': 'California', 'country': 'United States', 'facility': 'University of California San Diego', 'geoPoint': {'lat': 32.84727, 'lon': -117.2742}}, {'zip': '90048', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Cedars-Sinai Medical Center', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '92868', 'city': 'Orange', 'state': 'California', 'country': 'United States', 'facility': 'University of California, Irvine', 'geoPoint': {'lat': 33.78779, 'lon': -117.85311}}, {'zip': '95817', 'city': 'Sacramento', 'state': 'California', 'country': 'United States', 'facility': 'University of California Davis Medical Center', 'geoPoint': {'lat': 38.58157, 'lon': -121.4944}}, {'zip': '94115', 'city': 'San Francisco', 'state': 'California', 'country': 'United States', 'facility': 'Forbes Norris MDA/ALS Research Center', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'zip': '94305', 'city': 'Stanford', 'state': 'California', 'country': 'United States', 'facility': 'Stanford Hospital and Clinics', 'geoPoint': {'lat': 37.42411, 'lon': -122.16608}}, {'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'country': 'United States', 'facility': 'University of Colorado Hospital Anschutz Outpatient Pavilion', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'zip': '06053', 'city': 'New Britain', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Hospital for Special Care', 'geoPoint': {'lat': 41.66121, 'lon': -72.77954}}, {'zip': '20037', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'country': 'United States', 'facility': 'George Washington University Medical Center', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'zip': '32224', 'city': 'Jacksonville', 'state': 'Florida', 'country': 'United States', 'facility': 'Mayo Clinic', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'zip': '33136', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'University of Miami', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33612', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'Carol and Frank Morsini Center for Advanced Health Care - University of South Florida', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '30322', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'The Emory Clinic', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '30912', 'city': 'Augusta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Georgia Regents University', 'geoPoint': {'lat': 33.47097, 'lon': -81.97484}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Northwestern University Feinberg School of Medicine', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '46202', 'city': 'Indianapolis', 'state': 'Indiana', 'country': 'United States', 'facility': 'Indiana University', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'zip': '52242', 'city': 'Iowa City', 'state': 'Iowa', 'country': 'United States', 'facility': 'University of Iowa Hospitals and Clinics', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}}, {'zip': '66160', 'city': 'Kansas City', 'state': 'Kansas', 'country': 'United States', 'facility': 'University of Kansas Medical Center', 'geoPoint': {'lat': 39.11417, 'lon': -94.62746}}, {'zip': '21287', 'city': 'Baltimore', 'state': 'Maryland', 'country': 'United States', 'facility': 'Johns Hopkins University', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'zip': '02114', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Massachusetts General Hospital', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '01655', 'city': 'Worcester', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'University of Massachusetts Memorial Medical Center', 'geoPoint': {'lat': 42.26259, 'lon': -71.80229}}, {'zip': '48109', 'city': 'Ann Arbor', 'state': 'Michigan', 'country': 'United States', 'facility': 'University of Michigan Hospital and Health System', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'zip': '48202', 'city': 'Detroit', 'state': 'Michigan', 'country': 'United States', 'facility': 'Henry Ford Health System', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '55415', 'city': 'Minneapolis', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Hennepin County Medical Center', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}, {'zip': '63104', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Saint Louis University', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '63110', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Barnes-Jewish Hospital', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '68506', 'city': 'Lincoln', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Neurology Associates', 'geoPoint': {'lat': 40.8, 'lon': -96.66696}}, {'zip': '03756', 'city': 'Lebanon', 'state': 'New Hampshire', 'country': 'United States', 'facility': 'Dartmouth Hitchcock Medical Center Dept of Neurology', 'geoPoint': {'lat': 43.64229, 'lon': -72.25176}}, {'zip': '10021', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Hospital for Special Surgery', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10032', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Neurological Institute Columbia University Medical Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '13210', 'city': 'Syracuse', 'state': 'New York', 'country': 'United States', 'facility': 'SUNY Upstate Medical University', 'geoPoint': {'lat': 43.04812, 'lon': -76.14742}}, {'zip': '28207', 'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Neurosciences Institute: Neurology - Charlotte', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '27705', 'city': 'Durham', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Duke Neurological Disorders Clinic', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}, {'zip': '27157', 'city': 'Winston-Salem', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Wake Forest University Health Sciences', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}}, {'zip': '43221', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'The Ohio State University Wexner Medical Center', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '97213', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Providence Brain and Spine Institute ALS Center', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '97239', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Oregon Health and Science Center', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '17033', 'city': 'Hershey', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Penn State Milton S. Hershey Medical Center', 'geoPoint': {'lat': 40.28592, 'lon': -76.65025}}, {'zip': '19107', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'The Penn Comprehensive Neuroscience Center', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '19140', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Temple University School of Medicine', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '37232', 'city': 'Nashville', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Vanderbilt University Medical Center', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '75214', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Texas Neurology', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Baylor College of Medicine', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'University of Texas Health Science Center', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '22908', 'city': 'Charlottesville', 'state': 'Virginia', 'country': 'United States', 'facility': 'University of Virgina Health System', 'geoPoint': {'lat': 38.02931, 'lon': -78.47668}}, {'zip': '98195', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'University of Washington Medical Center', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '26506', 'city': 'Morgantown', 'state': 'West Virginia', 'country': 'United States', 'facility': 'West Virginia University Department of Neurology', 'geoPoint': {'lat': 39.62953, 'lon': -79.9559}}, {'zip': '53226', 'city': 'Milwaukee', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'Froedtert Memorial Lutheran Hospital, Department of Neurology', 'geoPoint': {'lat': 43.0389, 'lon': -87.90647}}, {'zip': '3000', 'city': 'Leuven', 'state': 'Vlaams Brabant', 'country': 'Belgium', 'facility': 'UZ Leuven - Campus Gasthuisberg', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'zip': 'T3M 1M4', 'city': 'Calgary', 'state': 'Alberta', 'country': 'Canada', 'facility': 'University of Calgary', 'geoPoint': {'lat': 51.05011, 'lon': -114.08529}}, {'zip': 'T6G 1Z1', 'city': 'Edmonton', 'state': 'Alberta', 'country': 'Canada', 'facility': 'Edmonton Kaye Clinic', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'zip': 'E3B OC7', 'city': 'Fredericton', 'state': 'New Brunswick', 'country': 'Canada', 'facility': 'Stan Cassidy Centre for Rehabilitation', 'geoPoint': {'lat': 45.94541, 'lon': -66.66558}}, {'zip': 'B3H 1V7', 'city': 'Halifax', 'state': 'Nova Scotia', 'country': 'Canada', 'facility': 'QE II Health Sciences Centre, NHI Site', 'geoPoint': {'lat': 44.64269, 'lon': -63.57688}}, {'zip': 'L8N 4K1', 'city': 'Hamilton', 'state': 'Ontario', 'country': 'Canada', 'facility': 'McMaster University Medical Centre', 'geoPoint': {'lat': 43.25011, 'lon': -79.84963}}, {'zip': 'N6A 5A5', 'city': 'London', 'state': 'Ontario', 'country': 'Canada', 'facility': 'London Health Sciences Centre', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'zip': 'M4N 3M5', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Sunnybrook Health Sciences Centre', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'H2L 4M1', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Notre-Dame Hospital/CHUM', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': 'H3A 2B4', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Montreal Neurological Institute and Hospital', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': 'G1J 1Z4', 'city': 'Québec', 'country': 'Canada', 'facility': "CHU de Quebec - Universite Laval Hopital de l'Enfant-Jesus", 'geoPoint': {'lat': 46.81228, 'lon': -71.21454}}, {'zip': '59037', 'city': 'Lille', 'country': 'France', 'facility': 'Hopital R. Salengro, CHRU Lille', 'geoPoint': {'lat': 50.63391, 'lon': 3.05512}}, {'zip': '87042', 'city': 'Limoges', 'country': 'France', 'facility': 'CHU Dupuytren', 'geoPoint': {'lat': 45.83362, 'lon': 1.24759}}, {'zip': '13005', 'city': 'Marseille', 'country': 'France', 'facility': 'Hopital de la Timone', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'zip': '34295', 'city': 'Montpellier', 'country': 'France', 'facility': 'Hopital Gui de Chauliac', 'geoPoint': {'lat': 43.61093, 'lon': 3.87635}}, {'zip': '06001', 'city': 'Nice', 'country': 'France', 'facility': 'CHU de Nice - Hopital Pasteur 2', 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'zip': '75651', 'city': 'Paris', 'country': 'France', 'facility': 'Hopital de la Salpetriere', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '37044', 'city': 'Tours', 'country': 'France', 'facility': 'Bretonneau University Hospital', 'geoPoint': {'lat': 47.39484, 'lon': 0.70398}}, {'zip': '89081', 'city': 'Ulm', 'state': 'Baden-Wurttemberg', 'country': 'Germany', 'facility': 'University of Ulm, Department of Neurology', 'geoPoint': {'lat': 48.39841, 'lon': 9.99155}}, {'zip': '30625', 'city': 'Hanover', 'state': 'Lower Saxony', 'country': 'Germany', 'facility': 'Hannover Medical School, Department of Neurology', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}}, {'zip': '13353', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Charite Campus Virchow-Klinikum, Neurology Department', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': 'Dublin 9', 'city': 'Dublin', 'country': 'Ireland', 'facility': 'Clinical Research Centre, Beaumont Hospital', 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}, {'zip': '20149', 'city': 'Milan', 'country': 'Italy', 'facility': 'IRCCS Istituto Auxologico Italiano - U.O. Neurologia', 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}}, {'zip': '20162', 'city': 'Milan', 'country': 'Italy', 'facility': 'Centro Clinico NEMO - Fondazione Serena Onlus, ASST Grande Ospedale Metropolitano Niguarda', 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}}, {'zip': '10126', 'city': 'Torino', 'country': 'Italy', 'facility': 'Dipartimento di Neuroscienze "Rita Levi Moltalcini" A.O.U. Citta della Salute e della Scienza di Torino P.O. "Molinette"', 'geoPoint': {'lat': 44.88856, 'lon': 11.99138}}, {'zip': '3584 CX', 'city': 'Utrecht', 'country': 'Netherlands', 'facility': 'University Medical Center Utrecht', 'geoPoint': {'lat': 52.09083, 'lon': 5.12222}}, {'zip': '1649-035', 'city': 'Lisbon', 'country': 'Portugal', 'facility': 'Hospital Santa Maria-Centro Hospitalar Lisboa Norte', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}, {'zip': '28016', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital San Rafael', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': 'PL6 8DH', 'city': 'Plymouth', 'state': 'Devon', 'country': 'United Kingdom', 'facility': 'Derriford Hospital', 'geoPoint': {'lat': 50.37153, 'lon': -4.14305}}, {'zip': 'L9 7LJ', 'city': 'Liverpool', 'country': 'United Kingdom', 'facility': 'Walton Centre for Neurology and Neurosurgery', 'geoPoint': {'lat': 53.41058, 'lon': -2.97794}}, {'zip': 'E1 2AT', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Clinical Research Centre, Royal London Hospital', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SE59RS', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Kings College Hospital', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}], 'overallOfficials': [{'name': 'MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Cytokinetics'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Cytokinetics', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}